Genomics and cancer drug resistance

Current Pharmaceutical Biotechnology

Volumn 13, Issue 5, 2012, Pages 651-673

  Rodrigues, António S ^a   Dinis, Joana ^a   Gromicho, Marta ^a   Martins, Célia ^a   Laires, António ^a,b   Rueff, José ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

ABC transporters; Apoptosis; Chronic myeloid leukemia; DNA repair; Drug resistance; Gene expression; Growth receptors; MicroRNAs

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 O BENZYLGUANINE; AEG 35156; AT 406; BORTEZOMIB; CANERTINIB; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYTARABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; HGS 1029; IDARUBICIN; INIPARIB; INO 1001; ISOSORBIDE; METHOXYAMINE; MICRORNA; NAVELBINE; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; OLAPARIB; PACLITAXEL; PELITINIB; PEMETREXED; RETASPIMYCIN; RITUXIMAB; RUCAPARIB; TANESPIMYCIN; TARIQUIDAR; TEMOZOLOMIDE; TERAMEPROCOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

ADVANCED CANCER; BREAST CANCER; CANCER RESISTANCE; CELL DEATH; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DNA DAMAGE; DNA REPAIR; DRUG TRANSPORT; GENE EXPRESSION; GENETIC ASSOCIATION; GENOMICS; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; IN VITRO STUDY; LEUKEMIA; LUNG CANCER; LUNG SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MELANOMA; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; OVARY CANCER; PROSTATE CANCER; REVIEW; SARCOMA; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER; UTERUS CARCINOMA;

DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; GENOMICS; HUMANS; NEOPLASMS;

EID: 84860265107     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112799857549     Document Type: Review

References (230)

1. Vasey, P. A. Ovarian cancer: front-line standard treatment in 2008. Ann. Oncol., 2008, 19 (Suppl 7), vii61-66.
2. Harries, M.; Gore, M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol., 2002, 3, 529-536.
3. Bookman, M. A. Standard treatment in advanced ovarian cancer in 2005: the state of the art. Int. J. Gynecol. Cancer, 2005, 15 (Suppl 3), 212-220.
4. Vasey, P. A. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br. J. Cancer, 2003, 89 (Suppl 3), S23-28.
5. Danesi, R.; de Braud, F.; Fogli, S.; de Pas, T. M.; Di Paolo, A.; Curigliano, G.; Del Tacca, M. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol. Rev., 2003, 55, 57-103.
6. Jassem, J. Chemotherapy of advanced non-small cell lung cancer. Ann. Oncol., 1999, 10 (Suppl 6), 77-82.
7. Harris, L.; Fritsche, H.; Mennel, R.; Norton, L.; Ravdin, P.; Taube, S.; Somerfield, M. R.; Hayes, D. F.; Bast, R. C. Jr; American Society of Clinical Oncology American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol., 2007, 25, 5287-5312.
8. Menard, S.; Valagussa, P.; Pilotti, S.; Gianni, L.; Biganzoli, E.; Boracchi, P.; Tomasic, G.; Casalini, P.; Marubini, E.; Colnaghi, M. I.; Cascinelli, N.; Bonadonna, G. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J. Clin. Oncol., 2001, 19, 329-335.
9. Etemadmoghadam, D.; deFazio, A.; Beroukhim, R.; Mermel, C.; George, J.; Getz, G.; Tothill, R.; Okamoto, A.; Raeder, M. B.; Harnett, P.; Lade, S.; Akslen, L. A.; Tinker, A. V.; Locandro, B.; Alsop, K.; Chiew, Y. E.; Traficante, N.; Fereday, S.; Johnson, D.; Fox, S.; Sellers, W.; Urashima, M.; Salvesen, H. B.; Meyerson, M.; Bowtell, D.; AOCS Study Group Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin. Cancer Res., 2009, 15, 1417-1427.
10. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer., 2002, 2, 48-58.
11. Sjoblom, T.; Jones, S.; Wood, L. D.; Parsons, D. W.; Lin, J.; Barber, T. D.; Mandelker, D.; Leary, R. J.; Ptak, J.; Silliman, N.; Szabo, S.; Buckhaults, P.; Farrell, C.; Meeh, P.; Markowitz, S. D.; Willis, J.; Dawson, D.; Willson, J. K.; Gazdar, A. F.; Hartigan, J.; Wu, L.; Liu, C.; Parmigiani, G.; Park, B. H.; Bachman, K. E.; Papadopoulos, N.; Vogelstein, B.; Kinzler, K. W.; Velculescu, V. E. The consensus coding sequences of human breast and colorectal cancers. Science, 2006, 314, 268-274.
12. Gillet, Jean-Pierre and Gottesman, Michael M. In: Mechanisms of Multidrug Resistance in Cancer; Zhao, J., Ed.; Multidrug Resistance in Cancer; Humana Press: New York, USA, 2010; pp 47-76.
13. Santarius, T.; Shipley, J.; Brewer, D.; Stratton, M. R.; Cooper, C. S. A census of amplified and overexpressed human cancer genes. Nat. Rev. Cancer., 2010, 10, 59-64.
14. Bates, S. E. In Foreword; Mehta, Kapil and Siddik, H. Zahid, Ed.; Drug Resistance in Cancer Cells; Springer: New York, USA, 2009; pp v-xi.
15. Liang, P.; Pardee, A. B. Analysing differential gene expression in cancer. Nat. Rev. Cancer., 2003, 3, 869-876.
16. Scherf, U.; Ross, D. T.; Waltham, M.; Smith, L. H.; Lee, J. K.; Tanabe, L.; Kohn, K. W.; Reinhold, W. C.; Myers, T. G.; Andrews, D. T.; Scudiero, D. A.; Eisen, M. B.; Sausville, E. A.; Pommier, Y.; Botstein, D.; Brown, P. O.; Weinstein, J. N. A gene expression database for the molecular pharmacology of cancer. Nat. Genet., 2000, 24, 236-244.
17. Haskell, C. M.; Canellos, G. P. L-Asparaginase resistance in human leukemia-asparagine synthetase. Biochem. Pharmacol., 1969, 18, 2578-2580.
18. Aslanian, A. M.; Fletcher, B. S.; Kilberg, M. S. Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem. J., 2001, 357, 321-328.
19. Holleman, A.; Cheok, M. H.; den Boer, M. L.; Yang, W.; Veerman, A. J.; Kazemier, K. M.; Pei, D.; Cheng, C.; Pui, C. H.; Relling, M. V.; Janka-Schaub, G. E.; Pieters, R.; Evans, W. E. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med., 2004, 351, 533-542.
20. Appel, I. M.; den Boer, M. L.; Meijerink, J. P.; Veerman, A. J.; Reniers, N. C.; Pieters, R. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood, 2006, 107, 4244-4249.
21. Stams, W. A.; den Boer, M. L.; Holleman, A.; Appel, I. M.; Beverloo, H. B.; van Wering, E. R.; Janka-Schaub, G. E.; Evans, W. E.; Pieters, R. Asparagine synthetase expression is linked with Lasparaginase resistance in TEL-AML1-negative but not TELAML1- positive pediatric acute lymphoblastic leukemia. Blood, 2005, 105, 4223-4225.
22. Dan, S.; Tsunoda, T.; Kitahara, O.; Yanagawa, R.; Zembutsu, H.; Katagiri, T.; Yamazaki, K.; Nakamura, Y.; Yamori, T. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res., 2002, 62, 1139-1147.
23. Staunton, J. E.; Slonim, D. K.; Coller, H. A.; Tamayo, P.; Angelo, M. J.; Park, J.; Scherf, U.; Lee, J. K.; Reinhold, W. O.; Weinstein, J. N.; Mesirov, J. P.; Lander, E. S.; Golub, T. R. Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. USA, 2001, 98, 10787-10792.
24. Rickardson, L.; Fryknas, M.; Dhar, S.; Lovborg, H.; Gullbo, J.; Rydaker, M.; Nygren, P.; Gustafsson, M. G.; Larsson, R.; Isaksson, A. Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br. J. Cancer, 2005, 93, 483-492.
25. Lee, J. K.; Havaleshko, D. M.; Cho, H.; Weinstein, J. N.; Kaldjian, E. P.; Karpovich, J.; Grimshaw, A.; Theodorescu, D. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc. Natl. Acad. Sci. USA, 2007, 104, 13086-13091.
26. Gyorffy, B.; Surowiak, P.; Kiesslich, O.; Denkert, C.; Schafer, R.; Dietel, M.; Lage, H. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int. J. Cancer, 2006, 118, 1699-1712.
27. Potti, A.; Dressman, H. K.; Bild, A.; Riedel, R. F.; Chan, G.; Sayer, R.; Cragun, J.; Cottrill, H.; Kelley, M. J.; Petersen, R.; Harpole, D.; Marks, J.; Berchuck, A.; Ginsburg, G. S.; Febbo, P.; Lancaster, J.; Nevins, J. R. Genomic signatures to guide the use of chemotherapeutics. Nat. Med., 2006, 12, 1294-1300.
28. Chang, J. C.; Wooten, E. C.; Tsimelzon, A.; Hilsenbeck, S. G.; Gutierrez, M. C.; Elledge, R.; Mohsin, S.; Osborne, C. K.; Chamness, G. C.; Allred, D. C.; O'Connell, P. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet, 2003, 362, 362-369.
29. van't Veer, L. J.; Bernards, R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature, 2008, 452, 564-570.
30. Lamb, J.; Crawford, E. D.; Peck, D.; Modell, J. W.; Blat, I. C.; Wrobel, M. J.; Lerner, J.; Brunet, J. P.; Subramanian, A.; Ross, K. N.; Reich, M.; Hieronymus, H.; Wei, G.; Armstrong, S. A.; Haggarty, S. J.; Clemons, P. A.; Wei, R.; Carr, S. A.; Lander, E. S.; Golub, T. R. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science, 2006, 313, 1929-1935.
31. Sorlie, T.; Perou, C. M.; Fan, C.; Geisler, S.; Aas, T.; Nobel, A.; Anker, G.; Akslen, L. A.; Botstein, D.; Borresen-Dale, A. L.; Lonning, P. E. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol. Cancer Ther., 2006, 5, 2914-2918.
32. Rosell, R.; Perez-Roca, L.; Sanchez, J. J.; Cobo, M.; Moran, T.; Chaib, I.; Provencio, M.; Domine, M.; Sala, M. A.; Jimenez, U.; Diz, P.; Barneto, I.; Macias, J. A.; de Las Penas, R.; Catot, S.; Isla, D.; Sanchez, J. M.; Ibeas, R.; Lopez-Vivanco, G.; Oramas, J.; Mendez, P.; Reguart, N.; Blanco, R.; Taron, M. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One, 2009, 4, e5133.
33. Cobo, M.; Isla, D.; Massuti, B.; Montes, A.; Sanchez, J. M.; Provencio, M.; Vinolas, N.; Paz-Ares, L.; Lopez-Vivanco, G.; Munoz, M. A.; Felip, E.; Alberola, V.; Camps, C.; Domine, M.; Sanchez, J. J.; Sanchez-Ronco, M.; Danenberg, K.; Taron, M.; Gandara, D.; Rosell, R. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J. Clin. Oncol., 2007, 25, 2747-2754.
34. Margeli, M.; Cirauqui, B.; Castella, E.; Tapia, G.; Costa, C.; Gimenez-Capitan, A.; Barnadas, A.; Sanchez Ronco, M.; Benlloch, S.; Taron, M.; Rosell, R. The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer. PLoS One, 2010, 5, e9499.
35. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2, 48-58.
36. Szakács, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov., 2006, 5, 219-234.
37. Gottesman, M. M.; Ling, V. The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research. FEBS Lett., 2006, 580, 998-1009.
38. Gillet, J.; Efferth, T.; Remacle, J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochimica et Biophysica Acta (BBA) - Rev. Cancer, 2007, 1775, 237-262.
39. Lage, H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol. Life Sci., 2008, 65, 3145-3167.
40. Boumendjel, A.; Boutonnat, J. and Robert, J., Eds.; In ABC Transporters and Multidrug Resistance; Wang, B., Ed.; Drug Discovery and Development; John Wiley & Sons, Inc.: Hoboken, New Jersey, USA, 2009
41. Chaudhary, P. M.; Roninson, I. B. Expression and activity of Pglycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell, 1991, 66, 85-94.
42. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer, 2005, 5, 275-284.
43. Clarke, M. F.; Dick, J. E.; Dirks, P. B.; Eaves, C. J.; Jamieson, C. H. M.; Jones, D. L.; Visvader, J.; Weissman, I. L.; Wahl, G. M. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res., 2006, 66, 9339-9344.
44. Fletcher, J. I.; Haber, M.; Henderson, M. J.; Norris, M. D. ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer., 2010, 10, 147-156.
45. Mirski, S. E. L.; Gerlach, J. H.; Cole, S. P. C. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res., 1987, 47, 2594-2598.
46. Chen, Y. N.; Mickley, L. A.; Schwartz, A. M.; Acton, E. M.; Hwang, J. L.; Fojo, A. T. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J. Biol. Chem., 1990, 265, 10073-10080.
47. Alvarez, M.; Paull, K.; Monks, A.; Hose, C.; Lee, J. S.; Weinstein, J.; Grever, M.; Bates, S.; Fojo, T. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the national cancer institute anticancer drug screen. J. Clin. Invest., 1995, 95, 2205-2214.
48. Szakács, G.; Annereau, J.; Lababidi, S.; Shankavaram, U.; Arciello, A.; Bussey, K. J.; Reinhold, W.; Guo, Y.; Kruh, G. D.; Reimers, M.; Weinstein, J. N.; Gottesman, M. M. Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells. Cancer Cell, 2004, 6, 129-137.
49. Bussey, K. J.; Chin, K.; Lababidi, S.; Reimers, M.; Reinhold, W. C.; Kuo, W. L.; Gwadry, F.; Ajay; Kouros-Mehr, H.; Fridlyand, J.; Jain, A.; Collins, C.; Nishizuka, S.; Tonon, G.; Roschke, A.; Gehlhaus, K.; Kirsch, I.; Scudiero, D. A.; Gray, J. W.; Weinstein, J. N. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol. Cancer. Ther., 2006, 5, 853-867.
50. Ma, Y.; Ding, Z.; Qian, Y.; Wan, Y. W.; Tosun, K.; Shi, X.; Castranova, V.; Harner, E. J.; Guo, N. L. An integrative genomic and proteomic approach to chemosensitivity prediction. Int. J. Oncol., 2009, 34, 107-115.
51. Ross, D. D.; Doyle, L. A. Mining our ABCs: Pharmacogenomic approach for evaluating transporter function in cancer drug resistance. Cancer Cell, 2004, 6, 105-107.
52. Marie, J.; Zittoun, R.; Sikic, B. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood, 1991, 78, 586-592.
53. Legrand, O.; Simonin, G.; Perrot, J.; Zittoun, R.; Marie, J. Pgp and MRP Activities Using Calcein-AM Are Prognostic Factors in Adult Acute Myeloid Leukemia Patients. Blood, 1998, 91, 4480-4488.
54. Wuchter, C.; Leonid, K.; Ruppert, V.; Schrappe, M.; Buchner, T.; Schoch, C.; Haferlach, T.; Harbott, J.; Ratei, R.; Dorken, B.; Ludwig, W. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica, 2000, 85, 711-721.
55. Benderra, Z.; Faussat, A.; Sayada, L.; Perrot, J.; Chaoui, D.; Marie, J.; Legrand, O. Breast Cancer Resistance Protein and PGlycoprotein in 149 Adult Acute Myeloid Leukemias. Clin. Cancer Res., 2004, 10, 7896-7902.
56. Steinbach, D.; Legrand, O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia, 2007, 21, 1172-1176.
57. Steinbach, D.; Furchtbar, S.; Sell, W.; Lengemann, J.; Hermann, J.; Zintl, F.; Sauerbrey, A. Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML. Leukemia, 2003, 17, 470-471.
58. Burger, H.; Foekens, J. A.; Look, M. P.; Meijer-van Gelder, M. E.; Klijn, J. G. M.; Wiemer, E. A. C.; Stoter, G.; Nooter, K. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer. Clin. Cancer Res., 2003, 9, 827-836.
59. Robey, R. W.; Polgar, O.; Deeken, J.; To, K. W.; Bates, S. E. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev., 2007, 26, 39-57.
60. Ohishi, Y.; Oda, Y.; Uchiumi, T.; Kobayashi, H.; Hirakawa, T.; Miyamoto, S.; Kinukawa, N.; Nakano, H.; Kuwano, M.; Tsuneyoshi, M. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin. Cancer Res., 2002, 8, 3767-3775.
61. Lemos, C.; Jansen, G.; Peters, G. J. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br. J. Cancer, 2008, 98, 857-862.
62. Bernaudin, J. F.; Fajac, A.; Fleury-Feith, J.; Kerrou, K.; and Lacave, R. In: ABC proteins and oncology: Expression, detection, and implication of ABC proteins in solid tumors; Boumendjel, A., Boutonnat, J., Robert, J., Eds.; ABC Transporters and Multidrug Resistance; John Wiley & Sons, Inc.: Hoboken, New Jersey, USA, 2009; pp 143-175.
63. Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov., 2006, 5, 219-234.
64. Becton, D.; Dahl, G. V.; Ravindranath, Y.; Chang, M. N.; Behm, F. G.; Raimondi, S. C.; Head, D. R.; Stine, K. C.; Lacayo, N. J.; Sikic, B. I.; Arceci, R. J.; Weinstein, H. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood, 2006, 107, 1315-1324.
65. Holt, B.; Lowenberg, B.; Burnett, A. K.; Knauf, W. U.; Shepherd, J.; Piccaluga, P. P.; Ossenkoppele, G. J.; Verhoef, G. E. G.; Ferrant, A.; Crump, M.; Selleslag, D.; Theobald, M.; Fey, M. F.; Vellenga, E.; Dugan, M.; Sonneveld, P.; on behalf of the Dutch- Belgian Hemato-Oncology Cooperative Group (HOVON) and the United Kingdom Medical Research Council (MRC), The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood, 2005, 106, 2646-2654.
66. Solary, E.; Drenou, B.; Campos, L.; de Cremoux, P.; Mugneret, F.; Moreau, P.; Lioure, B.; Falkenrodt, A.; Witz, B.; Bernard, M.; Hunault-Berger, M.; Delain, M.; Fernandes, J.; Mounier, C.; Guilhot, F.; Garnache, F.; Berthou, C.; Kara-Slimane, F.; Harousseau, J. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood, 2003, 102, 1202-1210.
67. Gandhi, L.; Harding, M. W.; Neubauer, M.; Langer, C. J.; Moore, M.; Ross, H. J.; Johnson, B. E.; Lynch, T. J. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer, 2007, 109, 924-932.
68. Kroemer, G.; Galluzzi, L.; Vandenabeele, P.; Abrams, J.; Alnemri, E. S.; Baehrecke, E. H.; Blagosklonny, M. V.; El-Deiry, W. S.; Golstein, P.; Green, D. R.; Hengartner, M.; Knight, R. A.; Kumar, S.; Lipton, S. A.; Malorni, W.; Nunez, G.; Peter, M. E.; Tschopp, J.; Yuan, J.; Piacentini, M.; Zhivotovsky, B.; Melino, G.; Nomenclature committee on cell death 2009 classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ., 2009, 16, 3-11.
69. Kerr, J. F.; Wyllie, A. H.; Currie, A. R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer, 1972, 26, 239-257.
70. Fojo, T.; Bates, S. Strategies for reversing drug resistance. Oncogene, 2003, 22, 7512-7523.
71. Tolomeo, M.; Simoni, D. Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies. Curr. Med. Chem. Anticancer Agents, 2002, 2, 387-401.
72. Johnstone, R. W.; Ruefli, A. A.; Lowe, S. W. Apoptosis: A Link between Cancer Genetics and Chemotherapy. Cell, 2002, 108, 153-164.
73. Kang, M. H.; Reynolds, C. P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res., 2009, 15, 1126-1132.
74. Tsujimoto, Y.; Cossman, J.; Jaffe, E.; Croce, C. M. Involvement of the bcl-2 gene in human follicular lymphoma. Science, 1985, 228, 1440-1443.
75. Adams, J. M.; Cory, S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene, 2007, 26, 1324-1337.
76. Reed, J. C. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood, 2008, 111, 3322-3330.
77. Yip, K. W.; Reed, J. C. Bcl-2 family proteins and cancer. Oncogene, 2008, 27, 6398-6406.
78. Bonetti, A.; Zaninelli, M.; Leone, R.; Cetto, G. L.; Pelosi, G.; Biolo, S.; Menghi, A.; Manfrin, E.; Bonetti, F.; Piubello, Q. bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin. Cancer Res., 1998, 4, 2331-2336.
79. Amundson, S. A.; Myers, T. G.; Scudiero, D.; Kitada, S.; Reed, J. C.; Fornace, A. J., Jr An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res., 2000, 60, 6101-6110.
80. Warr, M. R.; Shore, G. C. Small-molecule Bcl-2 antagonists as targeted therapy in oncology. Curr. Oncol., 2008, 15, 256-261.
81. Danial, N. N.; Korsmeyer, S. J. Cell death: critical control points. Cell, 2004, 116, 205-219.
82. Hussain, S. R.; Cheney, C. M.; Johnson, A. J.; Lin, T. S.; Grever, M. R.; Caligiuri, M. A.; Lucas, D. M.; Byrd, J. C. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement- dependent cytotoxicity. Clin. Cancer Res., 2007, 13, 2144-2150.
83. Sieghart, W.; Losert, D.; Strommer, S.; Cejka, D.; Schmid, K.; Rasoul-Rockenschaub, S.; Bodingbauer, M.; Crevenna, R.; Monia, B. P.; Peck-Radosavljevic, M.; Wacheck, V. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J. Hepatol., 2006, 44, 151-157.
84. Kaufmann, S. H.; Karp, J. E.; Svingen, P. A.; Krajewski, S.; Burke, P. J.; Gore, S. D.; Reed, J. C. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood, 1998, 91, 991-1000.
85. Sjöström, J.; Blomqvist, C.; von Boguslawski, K.; Bengtsson, N.; Mjaaland, I.; Malmström, P.; Ostenstadt, B.; Wist, E.; Valvere, V.; Takayama, S.; Reed, J. C.; Saksela, E. The predictive value of bcl-2, bax, bcl-xl, bag-1, fas, and fasl for chemotherapy response in advanced breast cancer. Clin. Cancer Res., 2002, 8, 811-816.
86. Malamou-Mitsi, V.; Gogas, H.; Dafni, U.; Bourli, A.; Fillipidis, T.; Sotiropoulou, M.; Vlachodimitropoulos, D.; Papadopoulos, S.; Tzaida, O.; Kafiri, G.; Kyriakou, V.; Markaki, S.; Papaspyrou, I.; Karagianni, E.; Pavlakis, K.; Toliou, T.; Scopa, C.; Papakostas, P.; Bafaloukos, D.; Christodoulou, C.; Fountzilas, G. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Annals Oncol., 2006, 17, 1504-1511.
87. Krug, L. M.; Miller, V. A.; Filippa, D. A.; Venkatraman, E.; Ng, K. K.; Kris, M. G. Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine. Lung Cancer, 2003, 39, 139-143.
88. Akgul, C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol. Life Sci., 2009, 66, 1326-1336.
89. Labi, V.; Grespi, F.; Baumgartner, F.; Villunger, A. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death Differ., 2008, 15, 977-987.
90. Paoluzzi, L.; Gonen, M.; Gardner, J. R.; Mastrella, J.; Yang, D.; Holmlund, J.; Sorensen, M.; Leopold, L.; Manova, K.; Marcucci, G.; Heaney, M. L.; O'Connor, O. A. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood, 2008, 111, 5350-5358.
91. Paoluzzi, L.; Gonen, M.; Bhagat, G.; Furman, R. R.; Gardner, J. R.; Scotto, L.; Gueorguiev, V. D.; Heaney, M. L.; Manova, K.; O'Connor, O. A. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood, 2008, 112, 2906-2916.
92. Reed, J. C. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat. Clin. Pract. Oncol., 2006, 3, 388-398.
93. Fulda, S. Targeting inhibitor of apoptosis proteins (iaps) for cancer therapy. Anti-Cancer Agents Med. Chem., 2008, 8, 533-539.
94. LaCasse, E. C.; Mahoney, D. J.; Cheung, H. H.; Plenchette, S.; Baird, S.; Korneluk, R. G. IAP-targeted therapies for cancer. Oncogene, 2008, 27(48), 6252-6275.
95. Kaufmann, S. H.; Vaux, D. L. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene, 2003, 22, 7414-7430.
96. Anguiano-Hernandez, Y.; Chartier, A.; Huerta, S. Smac/DIABLO and Colon Cancer. Anti-Cancer Agents Med. Chem., 2007, 7, 467-473.
97. Kumar, M. V.; Shirley, R.; Ma, Y.; Lewis, R. W. Role of genomics- based strategies in overcoming chemotherapeutic resistance. Curr. Pharm. Biotechnol., 2004, 5, 471-480.
98. Yang, L.; Cao, Z.; Yan, H.; Wood, W. C. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. Cancer Res., 2003, 63, 6815-6824.
99. Tamm, I.; Kornblau, S. M.; Segall, H.; Krajewski, S.; Welsh, K.; Kitada, S.; Scudiero, D. A.; Tudor, G.; Qui, Y. H.; Monks, A.; Andreeff, M.; Reed, J. C. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res., 2000, 6, 1796-1803.
100. Velculescu, V. E.; Madden, S. L.; Zhang, L.; Lash, A. E.; Yu, J.; Rago, C.; Lal, A.; Wang, C. J.; Beaudry, G. A.; Ciriello, K. M.; Cook, B. P.; Dufault, M. R.; Ferguson, A. T.; Gao, Y.; He, T. C.; Hermeking, H.; Hiraldo, S. K.; Hwang, P. M.; Lopez, M. A.; Luderer, H. F.; Mathews, B.; Petroziello, J. M.; Polyak, K.; Zawel, L.; Kinzler, K. W. Analysis of human transcriptomes. Nat. Genet., 1999, 23, 387-388.
101. Wright, C. W.; Duckett, C. S. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J. Clin. Invest., 2005, 115, 2673-2678.
102. Vucic, D. Targeting IAP (Inhibitor of Apoptosis) proteins for therapeutic intervention in tumors. Curr. Cancer Drug Targets, 2008, 8, 110-117.
103. Allgayer, H.; Fulda, S. An introduction to molecular targeted therapy of cancer. Adv. Med. Sci., 2008, 53, 130-138.
104. Fulda, S. Inhibitor of apoptosis proteins in hematological malignancies. Leukemia, 2009, 23, 467-476.
105. Fulda, S. Targeting inhibitor of apoptosis proteins (IAPs) for cancer therapy. Anticancer Agents Med. Chem., 2008, 8, 533-539.
106. Vogler, M.; Walczak, H.; Stadel, D.; Haas, T. L.; Genze, F.; Jovanovic, M.; Gschwend, J. E.; Simmet, T.; Debatin, K. M.; Fulda, S. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res., 2008, 68, 7956-7965.
107. Sancar, A.; Lindsey-Boltz, L. A.; Unsal-Kacmaz, K.; Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem., 2004, 73, 39-85.
108. Lieberman, H. B. DNA damage repair and response proteins as targets for cancer therapy. Curr. Med. Chem., 2008, 15, 360-367.
109. Jackson, S. P.; Bartek, J. The DNA-damage response in human biology and disease. Nature, 2009, 461, 1071-1078.
110. Kelley, M. R.; Fishel, M. L. DNA repair proteins as molecular targets for cancer therapeutics. Anticancer Agents Med. Chem., 2008, 8, 417-425.
111. Helleday, T.; Petermann, E.; Lundin, C.; Hodgson, B.; Sharma, R. A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer., 2008, 8, 193-204.
112. Borst, P.; Rottenberg, S.; Jonkers, J. How do real tumors become resistant to cisplatin? Cell Cycle, 2008, 7, 1353-1359.
113. Drabløs, F.; Feyzi, E.; Aas, P. A.; Vaagbø, C. B.; Kavli, B.; Bratlie, M. S.; Peña-Diaz, J.; Otterlei, M.; Slupphaug, G.; Krokan, H. E. Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair, 2004, 3, 1389-1407.
114. Kaina, B.; Christmann, M.; Naumann, S.; Roos, W. P. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst), 2007, 6, 1079-1099.
115. Augustine, C. K.; Yoo, J. S.; Potti, A.; Yoshimoto, Y.; Zipfel, P. A.; Friedman, H. S.; Nevins, J. R.; Ali-Osman, F.; Tyler, D. S. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin. Cancer Res., 2009, 15, 502-510.
116. Kokkinakis, D. M.; Ahmed, M. M.; Delgado, R.; Fruitwala, M. M.; Mohiuddin, M.; Albores-Saavedra, J. Role of O6-Methylguanine- DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents. Cancer Res., 1997, 57, 5360-5368.
117. Hegi, M. E.; Liu, L.; Herman, J. G.; Stupp, R.; Wick, W.; Weller, M.; Mehta, M. P.; Gilbert, M. R. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol., 2008, 26, 4189-4199.
118. Hegi, M. E.; Diserens, A. C.; Godard, S.; Dietrich, P. Y.; Regli, L.; Ostermann, S.; Otten, P.; Van Melle, G.; de Tribolet, N.; Stupp, R. Clinical trial substantiates the predictive value of O-6- methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res., 2004, 10, 1871-1874.
119. Verbeek, B.; Southgate, T. D.; Gilham, D. E.; Margison, G. P. O6- Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br. Med. Bull., 2008, 85, 17-33.
120. Jiricny, J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol., 2006, 7, 335-346.
121. Li, G. M. Mechanisms and functions of DNA mismatch repair. Cell Res., 2008, 18, 85-98.
122. Casorelli, I.; Russo, M. T.; Bignami, M. Role of mismatch repair and MGMT in response to anticancer therapies. Anticancer Agents Med. Chem., 2008, 8, 368-380.
123. Hawn, M. T.; Umar, A.; Carethers, J. M.; Marra, G.; Kunkel, T. A.; Boland, C. R.; Koi, M. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res., 1995, 55, 3721-3725.
124. Povey, A. C.; Badawi, A. F.; Cooper, D. P.; Hall, C. N.; Harrison, K. L.; Jackson, P. E.; Lees, N. P.; O'Connor, P. J.; Margison, G. P. DNA alkylation and repair in the large bowel: animal and human studies. J. Nutr., 2002, 132, 3518S-3521S.
125. Robertson, A. B.; Klungland, A.; Rognes, T.; Leiros, I. DNA repair in mammalian cells: Base excision repair: the long and short of it. Cell Mol. Life Sci., 2009, 66, 981-993.
126. Moore, D. H.; Michael, H.; Tritt, R.; Parsons, S. H.; Kelley, M. R. Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers. Clin. Cancer Res., 2000, 6, 602-609.
127. Kelley, M. R.; Cheng, L.; Foster, R.; Tritt, R.; Jiang, J.; Broshears, J.; Koch, M. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin. Cancer Res., 2001, 7, 824-830.
128. Wang, D.; Luo, M.; Kelley, M. R. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol. Cancer. Ther., 2004, 3, 679-686.
129. Robertson, K. A.; Bullock, H. A.; Xu, Y.; Tritt, R.; Zimmerman, E.; Ulbright, T. M.; Foster, R. S.; Einhorn, L. H.; Kelley, M. R. Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res., 2001, 61, 2220-2225.
130. Bobola, M. S.; Finn, L. S.; Ellenbogen, R. G.; Geyer, J. R.; Berger, M. S.; Braga, J. M.; Meade, E. H.; Gross, M. E.; Silber, J. R. Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. Clin. Cancer Res., 2005, 11, 7405-7414.
131. Silber, J. R.; Bobola, M. S.; Blank, A.; Schoeler, K. D.; Haroldson, P. D.; Huynh, M. B.; Kolstoe, D. D. The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin. Cancer Res., 2002, 8, 3008-3018.
132. Fung, H.; Demple, B. A vital role for Ape1/Ref1 protein in repairing spontaneous DNA damage in human cells. Mol. Cell, 2005, 17, 463-470.
133. Bapat, A.; Fishel, M. L.; Kelley, M. R. Going ape as an approach to cancer therapeutics. Antioxid. Redox Signal., 2009, 11, 651-668.
134. Hoeijmakers, J. H. Genome maintenance mechanisms for preventing cancer. Nature, 2001, 411, 366-374.
135. Wood, R. D.; Mitchell, M.; Lindahl, T. Human DNA repair genes, 2005. Mutat. Res., 2005, 577, 275-283.
136. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 2007, 7, 573-584.
137. Kelland, L. R.; Mistry, P.; Abel, G.; Freidlos, F.; Loh, S. Y.; Roberts, J. J.; Harrap, K. R. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res., 1992, 52, 1710-1716.
138. Masters, J. R.; Koberle, B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat. Rev. Cancer, 2003, 3, 517-525.
139. Welsh, C.; Day, R.; McGurk, C.; Masters, J. R.; Wood, R. D.; Koberle, B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int. J. Cancer, 2004, 110, 352-361.
140. Koberle, B.; Grimaldi, K. A.; Sunters, A.; Hartley, J. A.; Kelland, L. R.; Masters, J. R. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int. J. Cancer, 1997, 70, 551-555.
141. Johnson, S. W.; Perez, R. P.; Godwin, A. K.; Yeung, A. T.; Handel, L. M.; Ozols, R. F.; Hamilton, T. C. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol., 1994, 47, 689-697.
142. Johnson, S. W.; Swiggard, P. A.; Handel, L. M.; Brennan, J. M.; Godwin, A. K.; Ozols, R. F.; Hamilton, T. C. Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. Cancer Res., 1994, 54, 5911-5916.
143. Ferry, K. V.; Hamilton, T. C.; Johnson, S. W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem. Pharmacol., 2000, 60, 1305-1313.
144. Chang, I. Y.; Kim, M. H.; Kim, H. B.; Lee, D. Y.; Kim, S. H.; Kim, H. Y.; You, H. J. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem. Biophys. Res. Commun., 2005, 327, 225-233.
145. Dabholkar, M.; Bostick-Bruton, F.; Weber, C.; Bohr, V. A.; Egwuagu, C.; Reed, E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J. Natl. Cancer Inst., 1992, 84, 1512-1517.
146. Shirota, Y.; Stoehlmacher, J.; Brabender, J.; Xiong, Y. P.; Uetake, H.; Danenberg, K. D.; Groshen, S.; Tsao-Wei, D. D.; Danenberg, P. V.; Lenz, H. J. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol., 2001, 19, 4298-4304.
147. Olaussen, K. A.; Dunant, A.; Fouret, P.; Brambilla, E.; Andre, F.; Haddad, V.; Taranchon, E.; Filipits, M.; Pirker, R.; Popper, H. H.; Stahel, R.; Sabatier, L.; Pignon, J. P.; Tursz, T.; Le Chevalier, T.; Soria, J. C.; IALT Bio Investigators DNA repair by ERCC1 in nonsmall- cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med., 2006, 355, 983-991.
148. Lord, R. V.; Brabender, J.; Gandara, D.; Alberola, V.; Camps, C.; Domine, M.; Cardenal, F.; Sanchez, J. M.; Gumerlock, P. H.; Taron, M.; Sanchez, J. J.; Danenberg, K. D.; Danenberg, P. V.; Rosell, R. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res., 2002, 8, 2286-2291.
149. Weberpals, J.; Garbuio, K.; O'Brien, A.; Clark-Knowles, K.; Doucette, S.; Antoniouk, O.; Goss, G.; Dimitroulakos, J. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int. J. Cancer, 2009, 124, 806-815.
150. Panasci, L.; Paiement, J. P.; Christodoulopoulos, G.; Belenkov, A.; Malapetsa, A.; Aloyz, R. Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin. Cancer Res., 2001, 7, 454-461.
151. Wang, Z. M.; Chen, Z. P.; Xu, Z. Y.; Christodoulopoulos, G.; Bello, V.; Mohr, G.; Aloyz, R.; Panasci, L. C. In vitro evidence for homologous recombinational repair in resistance to melphalan. J. Natl. Cancer Inst., 2001, 93, 1473-1478.
152. Klein, H. L. The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst), 2008, 7, 686-693.
153. Wang, W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat. Rev. Genet., 2007, 8, 735-748.
154. Kennedy, R. D.; Quinn, J. E.; Mullan, P. B.; Johnston, P. G.; Harkin, D. P. The role of BRCA1 in the cellular response to chemotherapy. J. Natl. Cancer Inst., 2004, 96, 1659-1668.
155. Taron, M.; Rosell, R.; Felip, E.; Mendez, P.; Souglakos, J.; Ronco, M. S.; Queralt, C.; Majo, J.; Sanchez, J. M.; Sanchez, J. J.; Maestre, J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet., 2004, 13, 2443-2449.
156. Quinn, J. E.; Carser, J. E.; James, C. R.; Kennedy, R. D.; Harkin, D. P. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol. Oncol., 2009, 113, 134-142.
157. Quinn, J. E.; Kennedy, R. D.; Mullan, P. B.; Gilmore, P. M.; Carty, M.; Johnston, P. G.; Harkin, D. P. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res, 2003, 63, 6221-6228.
158. Husain, A.; He, G.; Venkatraman, E. S.; Spriggs, D. R. BRCA1 upregulation is associated with repair-mediated resistance to cisdiamminedichloroplatinum(II). Cancer Res., 1998, 58, 1120-1123.
159. De Ligio, J. T.; Velkova, A.; Zorio, D. A.; Monteiro, A. N. Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy? Anticancer Agents Med. Chem., 2009, 9, 543-549.
160. Margeli, M.; Cirauqui, B.; Castella, E.; Tapia, G.; Costa, C.; Gimenez-Capitan, A.; Barnadas, A.; Sanchez Ronco, M.; Benlloch, S.; Taron, M.; Rosell, R. The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer. PLoS One, 2010, 5, e9499.
161. Reguart, N.; Cardona, A. F.; Carrasco, E.; Gomez, P.; Taron, M.; Rosell, R. BRCA1: a new genomic marker for non-small-cell lung cancer. Clin. Lung Cancer, 2008, 9, 331-339.
162. Santarpia, M.; Altavilla, G.; Margeli, M.; Cirauqui, B.; Mesiti, M.; Cavallari, V.; Ramirez, J. L.; Sanchez-Ronco, M.; Santarpia, L.; Taron, M.; Rosell, R. PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance. Cancer Invest., 2008, 26, 1044-1051.
163. Ashworth, A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol., 2008, 26, 3785-3790.
164. Martin, S. A.; Lord, C. J.; Ashworth, A. DNA repair deficiency as a therapeutic target in cancer. Curr. Opin. Genet. Dev., 2008, 18, 80-86.
165. Hendler, F. J.; Ozanne, B. W. Human squamous cell lung cancers express increased epidermal growth factor receptors. J. Clin. Invest., 1984, 74, 647-651.
166. Veale, D.; Ashcroft, T.; Marsh, C.; Gibson, G. J.; Harris, A. L. Epidermal growth factor receptors in non-small cell lung cancer. Br. J. Cancer, 1987, 55, 513-516.
167. Hynes, N. E.; Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer, 2005, 5, 341-354.
168. Amit, I.; Wides, R.; Yarden, Y. Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol. Syst. Biol., 2007, 3, 151.
169. Baselga, J.; Swain, S. M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer, 2009, 9, 463-475.
170. Marmor, M. D.; Skaria, K. B.; Yarden, Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys., 2004, 58, 903-913.
171. Mosesson, Y.; Yarden, Y. Oncogenic growth factor receptors: implications for signal transduction therapy. Semin. Cancer Biol., 2004, 14, 262-270.
172. Citri, A.; Yarden, Y. EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol., 2006, 7, 505-516.
173. Schulze, A.; Lehmann, K.; Jefferies, H. B. J.; McMahon, M.; Downward, J. Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev., 2001, 15, 981-994.
174. Ford, A. C.; Grandis, J. R. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck, 2003, 25, 67-73.
175. Ross, J. S.; Fletcher, J. A.; Linette, G. P.; Stec, J.; Clark, E.; Ayers, M.; Symmans, W. F.; Pusztai, L.; Bloom, K. J. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist, 2003, 8, 307-325.
176. Sharma, S. V.; Bell, D. W.; Settleman, J.; Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer, 2007, 7, 169-181.
177. Ambros, V. microRNAs: tiny regulators with great potential. Cell, 2001, 107, 823-826.
178. Breving, K.; Esquela-Kerscher, A. The complexities of microRNA regulation: mirandering around the rules. Int. J. Biochem. Cell Biol., 2009, 42(8),1316-1329.
179. Miska, E. A. How microRNAs control cell division, differentiation and death. Curr. Opin. Genet. Dev., 2005, 15, 563-568.
180. Griffiths-Jones, S. miRBase: microRNA sequences and annotation. Curr. Protoc. Bioinf., 2010, Chap.12, Unit 12.9.1-10.
181. Griffiths-Jones, S. The microRNA Registry. Nucleic Acids Res., 2004, 32, D109-11.
182. Lewis, B. P.; Burge, C. B.; Bartel, D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005, 120, 15-20.
183. Calin, G. A.; Sevignani, C.; Dumitru, C. D.; Hyslop, T.; Noch, E.; Yendamuri, S.; Shimizu, M.; Rattan, S.; Bullrich, F.; Negrini, M.; Croce, C. M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA, 2004, 101, 2999-3004.
184. Calin, G. A.; Ferracin, M.; Cimmino, A.; Di Leva, G.; Shimizu, M.; Wojcik, S. E.; Iorio, M. V.; Visone, R.; Sever, N. I.; Fabbri, M.; Iuliano, R.; Palumbo, T.; Pichiorri, F.; Roldo, C.; Garzon, R.; Sevignani, C.; Rassenti, L.; Alder, H.; Volinia, S.; Liu, C. G.; Kipps, T. J.; Negrini, M.; Croce, C. M. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med., 2005, 353, 1793-1801.
185. Iorio, M. V.; Ferracin, M.; Liu, C. G.; Veronese, A.; Spizzo, R.; Sabbioni, S.; Magri, E.; Pedriali, M.; Fabbri, M.; Campiglio, M.; Menard, S.; Palazzo, J. P.; Rosenberg, A.; Musiani, P.; Volinia, S.; Nenci, I.; Calin, G. A.; Querzoli, P.; Negrini, M.; Croce, C. M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res., 2005, 65, 7065-7070.
186. Zheng, T.; Wang, J.; Chen, X.; Liu, L. Role of microRNA in anticancer drug resistance. Int. J. Cancer, 2010, 126, 2-10.
187. Kovalchuk, O.; Filkowski, J.; Meservy, J.; Ilnytskyy, Y.; Tryndyak, V. P.; Chekhun, V. F.; Pogribny, I. P. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer. Ther., 2008, 7, 2152-2159.
188. Zhu, H.; Wu, H.; Liu, X.; Evans, B. R.; Medina, D. J.; Liu, C. G.; Yang, J. M. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol., 2008, 76, 582-588.
189. van Jaarsveld, M. T.; Helleman, J.; Berns, E. M.; Wiemer, E. A. MicroRNAs in ovarian cancer biology and therapy resistance. Int. J. Biochem. Cell Biol., 2010, 42(8),1282-1290.
190. Climent, J.; Dimitrow, P.; Fridlyand, J.; Palacios, J.; Siebert, R.; Albertson, D. G.; Gray, J. W.; Pinkel, D.; Lluch, A.; Martinez-Climent, J. A. Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res., 2007, 67, 818-826.
191. Yang, H.; Kong, W.; He, L.; Zhao, J. J.; O'Donnell, J. D.; Wang, J.; Wenham, R. M.; Coppola, D.; Kruk, P. A.; Nicosia, S. V.; Cheng, J. Q. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res., 2008, 68, 425-433.
192. Sorrentino, A.; Liu, C. G.; Addario, A.; Peschle, C.; Scambia, G.; Ferlini, C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol. Oncol., 2008, 111, 478-486.
193. Miller, T. E.; Ghoshal, K.; Ramaswamy, B.; Roy, S.; Datta, J.; Shapiro, C. L.; Jacob, S.; Majumder, S. MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1. J. Biol. Chem., 2008, 283, 29897-29903.
194. Pan, Y.; Morris, M. E.; Yu, A. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol. Pharmacol., 2009, 75, 1374-1379.
195. Xia, L.; Zhang, D.; Du, R.; Pan, Y.; Zhao, L.; Sun, S.; Hong, L.; Liu, J.; Fan, D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer, 2008, 123, 372-379.
196. Laios, A.; O'Toole, S.; Flavin, R.; Martin, C.; Kelly, L.; Ring, M.; Finn, S. P.; Barrett, C.; Loda, M.; Gleeson, N.; D'Arcy, T.; McGuinness, E.; Sheils, O.; Sheppard, B.; O'Leary, J. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol. Cancer, 2008, 7, 35.
197. Garofalo, M.; Quintavalle, C.; Di Leva, G.; Zanca, C.; Romano, G.; Taccioli, C.; Liu, C. G.; Croce, C. M.; Condorelli, G. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene, 2008, 27, 3845-3855.
198. Fujita, Y.; Kojima, K.; Hamada, N.; Ohhashi, R.; Akao, Y.; Nozawa, Y.; Deguchi, T.; Ito, M. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem. Biophys. Res. Commun., 2008, 377, 114-119.
199. To, K. K. W.; Zhan, Z.; Litman, T.; Bates, S. E. Regulation of ABCG2 expression at the 3' untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microrna in the s1 colon cancer cell line. Mol. Cell. Biol., 2008, 28, 5147-5161.
200. Zhu, H.; Wu, H.; Liu, X.; Evans, B. R.; Medina, D. J.; Liu, C.; Yang, J. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem. Pharmacol., 2008, 76, 582-588.
201. Mishra, P. J.; Humeniuk, R.; Mishra, P. J.; Longo-Sorbello, G. S.; Banerjee, D.; Bertino, J. R. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl. Acad. Sci. USA, 2007, 104, 13513-13518.
202. Goto, Y.; Yue, L.; Yokoi, A.; Nishimura, R.; Uehara, T.; Koizumi, S.; Saikawa, Y. A Novel single-nucleotide polymorphism in the 3′- untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin. Cancer Res., 2001, 7, 1952-1956.
203. Blower, P. E.; Verducci, J. S.; Lin, S.; Zhou, J.; Chung, J. H.; Dai, Z.; Liu, C. G.; Reinhold, W.; Lorenzi, P. L.; Kaldjian, E. P.; Croce, C. M.; Weinstein, J. N.; Sadee, W. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol. Cancer. Ther., 2007, 6, 1483-1491.
204. Melo, J. V.; Barnes, D. J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer, 2007, 7, 441-453.
205. Wetzler, M.; Talpaz, M.; Van Etten, R. A.; Hirsh-Ginsberg, C.; Beran, M.; Kurzrock, R. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J. Clin. Invest, 1993, 92, 1925-1939.
206. Wong, S.; Witte, O. N. The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol., 2004, 22, 247-306.
207. Calabretta, B.; Perrotti, D. The biology of CML blast crisis. Blood, 2004, 103, 4010-4022.
208. Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 2001, 344, 1031-1037.
209. Kantarjian, H.; Giles, F.; Wunderle, L.; Bhalla, K.; O'Brien, S.; Wassmann, B.; Tanaka, C.; Manley, P.; Rae, P.; Mietlowski, W.; Bochinski, K.; Hochhaus, A.; Griffin, J. D.; Hoelzer, D.; Albitar, M.; Dugan, M.; Cortes, J.; Alland, L.; Ottmann, O. G. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med., 2006, 354, 2542-2551.
210. Talpaz, M.; Shah, N. P.; Kantarjian, H.; Donato, N.; Nicoll, J.; Paquette, R.; Cortes, J.; O'Brien, S.; Nicaise, C.; Bleickardt, E.; Blackwood-Chirchir, M. A.; Iyer, V.; Chen, T. T.; Huang, F.; Decillis, A. P.; Sawyers, C. L. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med., 2006, 354, 2531-2541.
211. Slupianek, A.; Schmutte, C.; Tombline, G.; Nieborowska-Skorska, M.; Hoser, G.; Nowicki, M. O.; Pierce, A. J.; Fishel, R.; Skorski, T. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol. Cell, 2001, 8, 795-806.
212. Slupianek, A.; Nowicki, M. O.; Koptyra, M.; Skorski, T. BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. DNA Repair (Amst), 2006, 5, 243-250.
213. Canitrot, Y.; Falinski, R.; Louat, T.; Laurent, G.; Cazaux, C.; Hoffmann, J. S.; Lautier, D.; Skorski, T. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood, 2003, 102, 2632-2637.
214. Canitrot, Y.; Laurent, G.; Astarie-Dequeker, C.; Bordier, C.; Cazaux, C.; Hoffmann, J. S. Enhanced expression and activity of DNA polymerase beta in chronic myelogenous leukemia. Anticancer Res., 2006, 26, 523-525.
215. Kronenwett, R.; Butterweck, U.; Steidl, U.; Kliszewski, S.; Neumann, F.; Bork, S.; Blanco, E. D.; Roes, N.; Graf, T.; Brors, B.; Eils, R.; Maercker, C.; Kobbe, G.; Gattermann, N.; Haas, R. Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia. Oncogene, 2005, 24, 5313-5324.
216. Diaz-Blanco, E.; Bruns, I.; Neumann, F.; Fischer, J. C.; Graef, T.; Rosskopf, M.; Brors, B.; Pechtel, S.; Bork, S.; Koch, A.; Baer, A.; Rohr, U. P.; Kobbe, G.; Haeseler, A.; Gattermann, N.; Haas, R.; Kronenwett, R. Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia, 2007, 21, 494-504.
217. Zheng, C.; Li, L.; Haak, M.; Brors, B.; Frank, O.; Giehl, M.; Fabarius, A.; Schatz, M.; Weisser, A.; Lorentz, C.; Gretz, N.; Hehlmann, R.; Hochhaus, A.; Seifarth, W. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia, 2006, 20, 1028-1034.
218. Schultheis, B.; Carapeti-Marootian, M.; Hochhaus, A.; Weisser, A.; Goldman, J. M.; Melo, J. V. Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood, 2002, 99, 1766-1775.
219. Radich, J. P.; Dai, H.; Mao, M.; Oehler, V.; Schelter, J.; Druker, B.; Sawyers, C.; Shah, N.; Stock, W.; Willman, C. L.; Friend, S.; Linsley, P. S. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA, 2006, 103, 2794-2799.
220. Mohty, M.; Yong, A. S.; Szydlo, R. M.; Apperley, J. F.; Melo, J. V. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood, 2007, 110, 380-383.
221. Frank, O.; Brors, B.; Fabarius, A.; Li, L.; Haak, M.; Merk, S.; Schwindel, U.; Zheng, C.; Muller, M. C.; Gretz, N.; Hehlmann, R.; Hochhaus, A.; Seifarth, W. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia, 2006, 20, 1400-1407.
222. Villuendas, R.; Steegmann, J. L.; Pollan, M.; Tracey, L.; Granda, A.; Fernandez-Ruiz, E.; Casado, L. F.; Martinez, J.; Martinez, P.; Lombardia, L.; Villalon, L.; Odriozola, J.; Piris, M. A. Identification of genes involved in imatinib resistance in CML: a geneexpression profiling approach. Leukemia, 2006, 20, 1047-1054.
223. Venturini, L.; Battmer, K.; Castoldi, M.; Schultheis, B.; Hochhaus, A.; Muckenthaler, M. U.; Ganser, A.; Eder, M.; Scherr, M. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood, 2007, 109, 4399-4405.
224. O'Donnell, K. A.; Wentzel, E. A.; Zeller, K. I.; Dang, C. V.; Mendell, J. T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature, 2005, 435, 839-843.
225. Faber, J.; Gregory, R. I.; Armstrong, S. A. Linking miRNA regulation to BCR-ABL expression: the next dimension. Cancer Cell, 2008, 13, 467-469.
226. Bueno, M. J.; Perez de Castro, I.; Gomez de Cedron, M.; Santos, J.; Calin, G. A.; Cigudosa, J. C.; Croce, C. M.; Fernandez-Piqueras, J.; Malumbres, M. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell, 2008, 13, 496-506.
227. Gromicho, M.; Dinis, J.; Martins, C.; Laires, A.; Rueff, J.; Rodrigues, A. Role of ABC transporters in the development of Imatinib resistance. Haematologica, 2009, 94 (supp 2), 344.
228. Dinis, J.; Gromicho, M.; Martins, C.; Laires, A.; Rueff, J.; Rodrigues, A. Evaluation of DSBS repair in Imatinib resistant cell lines. Haematologica, 2009, 94(suppl 2), 130.
229. Dolan, M. E.; Pegg, A. E. O6-benzylguanine and its role in chemotherapy. Clin. Cancer Res., 1997, 3, 837-847.
230. Plummer, R.; Jones, C.; Middleton, M.; Wilson, R.; Evans, J.; Olsen, A.; Curtin, N.; Boddy, A.; McHugh, P.; Newell, D.; Harris, A.; Johnson, P.; Steinfeldt, H.; Dewji, R.; Wang, D.; Robson, L.; Calvert, H. Phase I study of the poly (ADP-Ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res., 2008, 14, 7917-7923.